spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Biorelate offers free access to AI-based drug discovery tool: Galactic

Biorelate


27 May 2020: Biorelate, a UK-based AI start up, is offering all researchers free use of Galactic, its cloud-based web tool, to support biomedical researchwhile lab accessis restrictedaround the world.

Systematically analysingthe data available on targets, drugs and disease mechanisms from data repositories and academic papers takes researchers over a year on average. The cognitive computing platformbehind Galactic(Galactic-AI™)can speed up the research process by collecting and curatingmore than 30 million biomedical research text sources.With up to 80% of biomedicaldata thought to be unstructuredi, theplatformhelps researcherstogenerate a clearerview ofthecurrentstate of researchand gain invaluable insights.

In an open letterto cancer researchers, Cancer Research UK noted: “Universities are partially closed, laboratories have wound down their activities, experiments have stopped. Researchers are continuing to work productively from home, writing papers, analysing data, pulling together collaborations, reading the literature and generating ideas. But the progress of research will slow down, and this will inevitably have an impact on researchers’ careers and the lives of people affected by cancer.”

Dr. DanielJamieson, CEO and founder of Biorelate, commented: “As so many scientists focus onCOVID-19, a seriousrisk is that research into other diseases grindsto a halt. Our platform auto-curatesknowledge, helping researchersacross all diseaseareasmake better useof allthe existingand emergingscientific data locked away in text.We very much hope that with the release of Galactic, a browser-ready search engine to our platform,researchers will be able to take advantage of potential insights into focal points of research, such as drug targets and indications, at a time when they are more limited to desk-based activities.”

KevinCox, Chairman of Biorelate,added: “We believe that Galactic has an important role to play in helping those involved in drug discovery to continuetheir research and ensurewe get new therapies to patients without delay. We’re pleased to be offering free access to theGalacticweb appat a time when researchers are in desperate need ofthis kind of resourceand support. We have had very positive feedback from early adopters, who are using the tooltofind causally related data and perform systematic andpragmatic reviews.”

Users of the Galactic web tool can navigate Galactic’s tailored portalstofind research, experts,organisationsand hidden insights–such as causal interactions –and make hypotheses and predictionswhile saving significant time and resources.The tool also offers more technical functionality for large enterprises who want to input their own textual content and ontologies they’ve designed in house.

For more data science or informatics-led activities, Biorelate offersdirect access to curated data from the platform, to provide, for example, novel causal interactionsthat can be used to investigate biological pathways and study the impact of drugs on specific disease models. Biorelatealso offersbespoke services in using the platform, Galactic-AI™, in combination with data science expertise to help solve and answer important drug discovery questions.Their expertsput togetherevidenceandrationale and bridge the gaps in a customer’s understanding of targets/indications to guide their clinical strategy.To access the free Galactic tool, registerhere: https://bit.ly/2X3fDvp. For more information about Biorelate and Galactic-AI, visit: www.biorelate.com
email info@biorelate.com
web https://www.biorelate.com/
email Unit 9, Williams House, Manchester Science Park, Lloyd St N, Manchester M15 6SE
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Huge boom in Korean Pharma reported at CPhI Korea

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event.
More info >>


White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement